# US 2022/0033882 A1 · Methods of diagnosing and treating patients with pigmented skin lesions

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0033882 A1
- Document ID: US20220033882A1
- Status: Published application
- Kind: A1
- Application number: 17/392,706
- Filed: 2021-08-03
- Published: 2022-02-03
- Earliest claimed: 2020-08-03
- Assignees: Castle Biosciences, Inc.
- Applicants: Castle Biosciences, Inc.
- Inventors: Robert Willis COOK; Derek MAETZOLD; Kyle R. COVINGTON; Olga ZOLOCHEVSKA
- Web page: https://patentgrep.com/patent/US20220033882A1

## CPC

- C12Q 1/6809: Methods for determination or identification of nucleic acids involving differential detection
- C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575)
- C12Q 1/6806: Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay (C12Q1/6804 takes precedence)
- G16B 5/20: Probabilistic models
- G16B 20/20: Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
- G16B 25/10: Gene or protein expression profiling; Expression-ratio estimation or normalisation
- G16B 40/00: ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
- G16H 50/20: for computer-aided diagnosis, e.g. based on medical expert systems
- G16H 50/30: for calculating health indices; for individual health risk assessment
- C12Q 2600/158: Expression markers
- C12Q 2600/166: Oligonucleotides used as internal standards, controls or normalisation probes
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- G16B: BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16H: HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA

## Abstract

The present disclosure relates to methods for diagnosing a skin lesion as malignant or benign.

## Claims

### Claim 1

A method for treating a patient with a skin lesion, the method comprising:
(a) obtaining a diagnosis identifying the skin lesion as a malignant lesion, an intermediate risk lesion, or a benign lesion in a sample from the skin lesion of the patient, wherein the diagnosis was obtained by:
(1) determining the expression level of at least 12 genes in a gene set; wherein the at least 12 genes in the gene set are selected from:
ABLIM1, ANXA8L1, ATP6V0E2, BAP1, BCL2A1, BTG1, CLCA2, CST6, CSTA, CXCL14, DCT, DSP, DUSP4, GATA3, GJA1, GPR143, HAL, MGP, KLF5, KRT2, KRT17, NES, PPL, RPL37A, PTN, RPS16, S100A8, S100A9, SAP130, SFN, TP63, and WIPI1;
(2) comparing the expression levels of the at least 12 genes in the gene set from the sample to the expression levels of the at least 12 genes in the gene set from a predictive training set to generate a probability score;
(3) providing an indication as to whether the skin lesion is a malignant lesion, an intermediate risk lesion, or a benign lesion based on the probability score generated in step (2); and
(4) identifying that the skin lesion is a malignant lesion based on the probability score; and
(b) administering to the patient an aggressive treatment when the determination is made in the affirmative that the patient has a skin lesion that is a malignant lesion.

### Claim 2 (depends on 1)

The method of claim 1, further comprising performing a resection of the skin lesion when the determination is made in the affirmative that the patient has a skin lesion that is a malignant lesion.

### Claim 3 (depends on 1)

The method of claim 1, wherein the expression level of each gene in a gene set is determined by reverse transcribing the isolated mRNA and measuring a level of fluorescence for each gene in the gene set by a nucleic acid sequence detection system following RT-PCR.

### Claim 4 (depends on 1)

The method of claim 1, wherein the sample from the skin lesion is obtained from a formalin-fixed, paraffin embedded sample.

### Claim 5 (depends on 1)

The method of claim 1, wherein the probability score is between 0 and 1, and wherein a value of 1 indicates a higher probability of a malignant lesion than a value of 0.

### Claim 6 (depends on 1)

The method of claim 1, wherein the probability score has a sensitivity of at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%, and/or has a specificity of at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%.

### Claim 7 (depends on 1)

The method of claim 1, wherein the probability score has a positive predictive value (PPV) of at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%, and/or has a negative predictive value (NPV) of at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%.

### Claim 8 (depends on 1)

The method of claim 1, wherein the gene set further comprises at least one control gene, wherein the at least one control gene is selected from the group consisting of FXR1, HNRNPL, and YKT6.

### Claim 9 (depends on 8)

The method of claim 8, wherein the control genes are FXR1, HNRNPL, and YKT6.

### Claim 10

A method of treating a patient with a skin lesion, the method comprising administering an aggressive cancer treatment regimen to the patient,
wherein the patient has a skin lesion identified as a malignant lesion as generated by comparing the expression levels of at least 12 genes wherein the at least 12 genes are selected from ABLIM1, ANXA8L1, ATP6V0E2, BAP1, BCL2A1, BTG1, CLCA2, CST6, CSTA, CXCL14, DCT, DSP, DUSP4, GATA3, GJA1, GPR143, HAL, MGP, KLF5, KRT2, KRT17, NES, PPL, RPL37A, PTN, RPS16, S100A8, S100A9, SAP130, SFN, TP63, and WIPI1, from the skin lesion with the expression levels of the same at least 12 genes are selected from ABLIM1, ANXA8L1, ATP6V0E2, BAP1, BCL2A1, BTG1, CLCA2, CST6, CSTA, CXCL14, DCT, DSP, DUSP4, GATA3, GJA1, GPR143, HAL, MGP, KLF5, KRT2, KRT17, NES, PPL, RPL37A, PTN, RPS16, S100A8, S100A9, SAP130, SFN, TP63, and WIPI1 from a predictive training set.

### Claim 11 (depends on 10)

The method of claim 10, wherein the skin lesion is determined to be a malignant lesion, an intermediate risk lesion, or a benign lesion.

### Claim 12 (depends on 10)

The method of claim 10, wherein the gene set further comprises at least one control gene, wherein the at least one control gene is selected from the group consisting of FXR1, HNRNPL, and YKT6.

### Claim 13 (depends on 12)

The method of claim 12, wherein the control genes are FXR1, HNRNPL, and YKT6.

### Claim 14

A kit comprising primer pairs suitable for the detection and quantification of nucleic acid expression of at least 12 genes, wherein the at least 12 genes are selected from: ABLIM1, ANXA8L1, ATP6V0E2, BAP1, BCL2A1, BTG1, CLCA2, CST6, CSTA, CXCL14, DCT, DSP, DUSP4, GATA3, GJA1, GPR143, HAL, MGP, KLF5, KRT2, KRT17, NES, PPL, RPL37A, PTN, RPS16, S100A8, S100A9, SAP130, SFN, TP63, and WIPI1.

### Claim 15 (depends on 14)

The kit of claim 14, wherein the kit further comprises primer pairs suitable for the detection and quantification of nucleic acid expression of at least one control gene, wherein the at least one control gene is selected from the group consisting of FXR1, HNRNPL, and YKT6.

### Claim 16 (depends on 15)

The kit of claim 15, wherein the kit comprises primer pairs for 3 control genes, wherein the 3 control genes are FXR1, HNRNPL, and YKT6.

### Claim 17

A method for diagnosing a skin lesion from a patient as a malignant lesion, an intermediate risk lesion, or a benign lesion, the method comprising:
(a) obtaining a sample from the skin lesion from the patient and isolating mRNA from the sample;
(b) determining the expression level of at least 12 genes in a gene set; wherein the at least 12 genes in the gene set are selected from: ABLIM1, ANXA8L1, ATP6V0E2, BAP1, BCL2A1, BTG1, CLCA2, CST6, CSTA, CXCL14, DCT, DSP, DUSP4, GATA3, GJA1, GPR143, HAL, MGP, KLF5, KRT2, KRT17, NES, PPL, RPL37A, PTN, RPS16, S100A8, S100A9, SAP130, SFN, TP63, and WIPI1;
(c) comparing the expression levels of the at least 12 genes in the gene set from the sample to the expression levels of the at least 12 genes in the gene set from a predictive training set to generate a probability score; and
(d) providing an indication as to whether the skin lesion is a malignant lesion, an intermediate risk lesion, or a benign lesion, based on the probability score generated in step (c).

### Claim 18 (depends on 17)

The method of claim 17, wherein the expression level of each gene in the gene set is determined by reverse transcribing the isolated mRNA into cDNA and measuring a level of fluorescence for each gene in the gene set by a nucleic acid sequence detection system following Real-Time Polymerase Chain Reaction (RT-PCR).

### Claim 19 (depends on 17)

The method of claim 17, wherein the sample from the skin lesion is obtained from a formalin-fixed, paraffin embedded sample.

### Claim 20 (depends on 17)

The method of claim 17, wherein the probability score is between 0 and 1, and wherein a value of 1 indicates a higher probability of a malignant lesion than a value of 0.

### Claim 21 (depends on 17)

The method of claim 17, wherein the probability score has a sensitivity of at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%, and/or has a specificity of at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%.

### Claim 22 (depends on 17)

The method of claim 17, wherein the probability score has a positive predictive value (PPV) of at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%, and/or has a negative predictive value (NPV) of at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%.

### Claim 23 (depends on 17)

The method of claim 17, further comprising identifying the skin lesion as a malignant lesion based on the probability score, and administering to the patient an aggressive tumor treatment.

### Claim 24 (depends on 17)

The method of claim 17, wherein the gene set further comprises at least one control gene, wherein the at least one control gene is selected from the group consisting of FXR1, HNRNPL, and YKT6.

### Claim 25 (depends on 24)

The method of claim 24, wherein the control genes are FXR1, HNRNPL, and YKT6.

### Claim 26

A method for diagnosing a skin lesion from a patient as a malignant lesion, an intermediate risk lesion, or a benign lesion, the method comprising:
(a) obtaining a sample from skin lesion from the patient and isolating mRNA from the sample;
(b) determining the expression level of at least 12 genes in a gene set; wherein the at least 12 genes in the gene set are: ABLIM1, ANXA8L1, ATP6V0E2, BAP1, BCL2A1, BTG1, CLCA2, CST6, CSTA, CXCL14, DCT, DSP, DUSP4, GATA3, GJA1, GPR143, HAL, MGP, KLF5, KRT2, KRT17, NES, PPL, RPL37A, PTN, RPS16, S100A8, S100A9, SAP130, SFN, TP63, and WIPI1; and
(c) providing an indication as to whether the skin lesion is a malignant lesion, an intermediate risk lesion, or a benign lesion, based on the expression level of the at least 12 genes generated in step (b).

### Claim 27 (depends on 26)

The method of claim 26, wherein the expression level of each gene in the gene set is determined by reverse transcribing the isolated mRNA into cDNA and measuring a level of fluorescence for each gene in the gene set by a nucleic acid sequence detection system following Real-Time Polymerase Chain Reaction (RT-PCR).

### Claim 28 (depends on 26)

The method of claim 26, wherein the sample from the skin lesion is obtained from formalin-fixed, paraffin embedded sample.

### Claim 29 (depends on 26)

The method of claim 26, wherein the gene set further comprises at least one control gene, wherein the at least one control gene is selected from the group consisting of FXR1, HNRNPL, and YKT6.

### Claim 30 (depends on 29)

The method of claim 29, wherein the control genes are FXR1, HNRNPL, and YKT6.
